Introduction to the Theme “Pharmacological Individuality: New Insights and Strategies for Personalized and Precise Drug Treatment”

Literature Cited

1. 1.

   Schork NJ. 2015. Personalized medicine: time for one-person trials. Nature 520:609–11
   [Google Scholar]
2. 2.

   Pirmohamed M. 2023. Pharmacogenomics: current status and future perspectives. Nat. Rev. Genet. 24:350–62
   [Google Scholar]
3. 3.

   Lauschke VM, Zhou Y, Ingelman-Sundberg M 2024. Pharmacogenomics beyond single common genetic variants: the way forward. Annu. Rev. Pharmacol. Toxicol. 64:33–51
   [Google Scholar]
4. 4.

   Corpas M, Siddiqui MK, Soremekum O, Mathur R, Gill D, Fatumo S. 2024. Addressing ancestry and sex bias in pharmacogenomics. Annu. Rev. Pharmacol. Toxicol. 64:53–64
   [Google Scholar]
5. 5.

   Khamsi R. 2022. The quest for an all-inclusive human genome. Nature 603:378–81
   [Google Scholar]
6. 6.

   Tremmel R, Hofmann U, Haag M, Schaeffeler E, Schwab M. 2024. Circulating biomarkers instead of genotyping to establish metabolizer phenotypes. Annu. Rev. Pharmacol. Toxicol. 64:65–87
   [Google Scholar]
7. 7.

   Darwich AS, Polasek TM, Aronson JK, Ogunbenro K, Wright DFB et al. 2021. Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy. Annu. Rev. Pharmacol. Toxicol. 61:225–45
   [Google Scholar]
8. 8.

   Lévi FA, Okyar A, Hadadi E, Innominato PF, Ballesta A. 2024. Circadian regulation of drug responses: towards sex-specific and personalized chronotherapy. Annu. Rev. Pharmacol. Toxicol. 64:89–114
   [Google Scholar]
9. 9.

   Reinberg A, Halberg F. 1971. Circadian chronopharmacology. Annu. Rev. Pharmacol. Toxicol. 11:455–92
   [Google Scholar]
10. 10.

    Levi F, Schibler U. 2007. Circadian rhythms: mechanisms and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 47:593–628
    [Google Scholar]
11. 11.

    Reinberg AE 1992. Concepts of chronopharmacology. Annu. Rev. Pharmacol. Toxicol. 32:51–66
    [Google Scholar]
12. 12.

    Paschos GK, Baggs JE, Hogenesch JB, FitzGerald GE. 2010. Annu. Rev. Pharmacol. Toxicol. 50:187–214
13. 13.

    Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J. 2010. Circadian timing in cancer treatments. Annu. Rev. Pharmacol. Toxicol. 50:377–421
    [Google Scholar]
14. 14.

    Dallmann R, Brown SA, Gachon F. 2014. Chronopharmacology: new insights and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 54:339–61
    [Google Scholar]
15. 15.

    Cejas RB, Petrykey K, Sapkota Y, Burridge PW. 2024. Anthracycline toxicity: light at the end of the tunnel?. Annu. Rev. Pharmacol. Toxicol. 64:115–34
    [Google Scholar]
16. 16.

    Tasdighi E, Adhikari R, Almaadawy O, Leucker TM, Blaha MJ. 2024. LP(a): structure, genetics, associated cardiovascular risk, and emerging therapeutics. Annu. Rev. Pharmacol. Toxicol. 64:135–57
    [Google Scholar]
17. 17.

    Venkatesh KP, Brito G, Kamel Boulos MN. 2024. Health digital twins in life science and health care innovation. Annu. Rev. Pharmacol. Toxicol. 64:159–70
    [Google Scholar]
18. 18.

    Colloca L. 2024. The nocebo effect. Annu. Rev. Pharmacol. Toxicol. 64:171–90
    [Google Scholar]